Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01854567 · ClinicalTrials.gov registry record · Phase 3
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
A Phase 3 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT01854567 is a Phase 3 study that has completed, run by Mesoblast. The registered enrollment target is 49 participants.
The verdict
NCT01854567, a Phase 3 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.
Interventions
- BIOLOGICAL Infusion of one MPC expanded cord unit and one unexpanded cord unit
- BIOLOGICAL Infusion of two unexpanded cord blood units.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2013-08 |
| Est. Completion | 2017-05-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01854567
The ClinicalTrials.gov registry entry for NCT01854567 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mesoblast, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Infusion of one MPC expanded cord unit and one unexpanded cord unit is the first listed.
NCT01854567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01854567 about?
NCT01854567 is a clinical study titled "P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies". The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.
What is the current status of trial NCT01854567?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2013-08. Estimated completion is 2017-05-05.
What interventions are being tested in trial NCT01854567?
The interventions under investigation include: Infusion of one MPC expanded cord unit and one unexpanded cord unit (BIOLOGICAL), Infusion of two unexpanded cord blood units. (BIOLOGICAL).
Who is sponsoring clinical trial NCT01854567?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.